8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Market-Moving News for August 18th
XOS: 140% | Xos shares are trading higher after the company announced that it has been awarded a prototype Other Transaction Agreement by the United States Air Force to develop and deliver a deployable mobile charging
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Richest NFL Team Owners List: Who’s Most Connected to Stock Market?
The list of NFL team owners includes billionaires and families. Some of them are well connected to publicly traded companies.
Jim Cramer: This Tech Stock Is ‘Terrific’, Home Depot Takes Beating
Jim Cramer praises Akamai after strong results, rejects Builders FirstSource, and urges focus on profitable companies like Applied Digital.